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A Public Health Framework
for ScreeningMammography
Evidence-Based vs Politically Mandated Care
In November 2009, in the midst of acrimonious con-
gressional debates over the Affordable Care Act (ACA),
the US Preventive Services Task Force (USPSTF) up-
dated its breast cancer screening guidelines. The Task
Force recommended biennial mammography screen-
ing forwomenofaverage riskaged50to74years, spark-
ing a torrent of criticism. Although the ACA mandated
insurance coverage forUSPSTF-recommendedpreven-
tive services, itwent further formammography screen-
ing. Insteadof relyingon themost recentUSPSTFguide-
lines, Congress amended the ACA to require the
Department of Health and Human Services (DHHS) to
use its 2002 guidelines, which recommended screen-
ing every 1 to 2 years starting at age 40 years.
Last year, indraft formtheUSPSTFagainprovision-
ally recommended biannual screening for women be-
ginningat age50.1Yet, onDecember 18, includedwithin
a $1.15 trillion fiscal year (FY) 2016ConsolidatedAppro-
priationsAct (HR2029),Congressagain requiredtheuse
ofUSPSTF’s 2002guidelines. In otherwords, a political
body required the DHHS to follow outdated scientific
guidance.Althoughmanywomen’shealthadvocatesap-
plauded the congressional mandate, it actually under-
mineswomen’s rights tomake informeddecisionsbased
on the best scientific evidence. This Viewpoint high-
lights the societal risks of politically motivated man-
dates relating to public health guidelines.
The ACA’s Preventive ServicesMandate
Toremovefinancialbarriers, theACArequiresnongrand-
fathered private insurance plans to provide first-dollar
coverage (no co-payments, coinsurance, or deduct-
ibles) for evidence-basedpreventive services. TheACA
requires coverage for any preventive service receiving
a USPSTF A or B grade (at leastmoderate certainty of a
moderate or substantial net benefit). The ACA also re-
quires insurance coverage for preventive services rec-
ommended by other scientific bodies, such as the Ad-
visory Committee on Immunization Practices.
In 2009, theUSPSTFgave aCgrade tomammogra-
physcreeningforwomenofaverageriskaged40through
49years, and the Task Force reaffirmed this assessment
in 2016 when it released its final recommendation.1 A
C grade is commonlymisunderstood. It does not advise
againstscreening,butratherit indicatesmoderatecertainty
that there is small population-level benefit. Clinicians
shoulddiscussC-ratedserviceswithpatientsusingan in-
dividualized assessment of the patients’ risk factors and
preferences. Importantly, irrespectiveofUSPSTFrecom-
mendations,most insurers haveofferedmammography
coverage forwomenaged40 through49years.
Political controversy, however, continues to swirl.
TheFY2016ConsolidatedAppropriationsAct instructs
DHHS to interpret any reference to “current” USPSTF
breast cancer screening recommendations to mean
those issued “before 2009”—in other words, its 2002
recommendations. Essentially, Congress is requiring
health insurers to ignore modern scientific assess-
ments and instead use 14-year-old guidance.
The CumulativeWeight of Evidence
Whyhave theTaskForce’s recommendationsonscreen-
ing mammography been so controversial? Often
USPSTF guidelines are framed as gov-
ernment rationing of beneficial health
servicesasacost-savingmeasure.Yetthe
Task Force uses a rigorous scientific
methodology focusing on net health
benefits and does not take economic
cost into account. In the case of breast
cancer screening, the USPSTF relied on
4 systematic evidence reviews of ran-
domized controlled trials2 and other studies and data
from6 independentmodels.3Women in their 40swho
undergoscreeningmammographyexperienceahighfre-
quency and magnitude of avoidable harms (eg, false-
positive results, biopsies, andexcessive treatment) rela-
tive to the benefits.3
Highly respected scientific panels have drawn the
sameconclusions.Asearly as 1997, aNationalCancer In-
stitute (NCI) consensus panel arrived at similar results,
later overturnedbyNCI’s politically appointed advisory
board. In 2015, the American Cancer Society recom-
mended raising the starting age for routine mammog-
raphy from 40 to 45 years, with biennial testing begin-
ning at age 55.4 By declining to acknowledge scientific
progress,Congressmaydomoreharmthangoodtowo-
men’s health.
Politics vs Science
The ACA’s decision to link coverage for preventive ser-
vices directly to USPSTF grading has sparked contro-
versy. Because the ACA does not mandate coverage
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for lower-graded preventive services, USPSTF panels could be
placed under political pressure, perhaps relaxing evidentiary
standards, “knowing that every word…constitutes a statutory
mandate.”5 Indeed, political considerations surround debates on
mammography screening. Stakeholders with conflicts of interest
lobbied for mammography coverage. The Medical Imaging and
Technology Alliance said a coverage mandate would “safeguard
access to this important life-saving technology,” while the Ameri-
can College of Radiology framed the Task Force’s recommenda-
tions as potentially causing women in their 40s to develop illness
and die of cancer.6
There is also a real risk that Congress could further erode the
Task Force’s independence. The House’s version of 2016 omnibus
spending bill (whichwas not included in the final legislation)would
havedenied funding for any futureUSPSTFmammography recom-
mendation. SomemembersofCongresshavegone further, propos-
ing to alter the Task Force’s composition to include “stakeholders
from themedical products manufacturing community.”6
However, in2015 theUSPSTFasserted its scientific integrityand
independence from political influence: “the ACA has not influ-
enced themethodsorevidence thresholds the task forceuses toas-
signanA,B,orany lettergrade,nordoes the task forceconsider cov-
erage implicationswhenmaking recommendations.”7Regarding its
updated guidelines, the Task Force wrote, “the USPSTF cannot re-
interpret the science and exaggerate the net benefit [of screening
mammography] simply to ensure coverage.”7
Benefits of Evidence-Based Preventive Care
Relying on scientific evidence to guide preventive care coverage is
a surprisingly recent idea. Prior to the ACA, insurers had discretion
todeterminewhat screening, counseling, andvaccinations to cover
as they currently do for all health services. Consequently, insurers
paid for some preventive services that were shown to be ineffec-
tive, such as chest radiography for lung cancer screening in smok-
ers andelectrocardiography for coronaryheart disease screening in
low-risk adults. In contrast, most insurers did not pay for certain
highly effective services, such as counseling for smoking cessation
or alcohol misuse.
The ACA improved the consistency of preventive care across
healthplansby requiringcoverageofevidence-basedservices.Wid-
eningaccess toeffectiveprevention,policymakers reasoned,would
improve the health of the nation. However, Congress’s decision to
assigndisproportionatevalue tobreast cancer comparedwithother
conditions thatmiddle-aged andolderwomenexperience (eg, car-
diovascular disease) has a social cost. Since health care dollars are
limited, devoting resources to marginally effective preventive ser-
vices in agroupwith lowdisease rates results in fewer resourcesde-
voted tomore effective (and cost-effective) services.
Importantly, the ACA neither discourages nor prevents insur-
ers frompaying forpreventive serviceswithaCor I grade,whichde-
notes a marginal population benefit or insufficient evidence to as-
sess thebalanceofbenefitsandharms. In thecaseofmammography,
approximately 1 in every 3400 women in their 40s screened over
10 years will avoid a cancer death compared with those not
screened.2 Insurers could consider the evidence and determine
whether the overall health benefit to their customers is worth the
aggregate annual expense.
Undermining Science
WhenCongress requiredDHHS to link insurance coveragepolicy to
outdated public health guidance, it was making a scientific judg-
ment for which it is distinctly unqualified. In effect, legislators im-
plicitly concluded that a rigorous assessment of numerous re-
search studies during the past 14 years is not relevant to women’s
health today.
The ACA improved the public’s health by guaranteeing that in-
surersprovideuniform,cost-freeaccess topreventiveservicesbased
on modern evidence of effectiveness. The public’s health is best
served when women’s personal decisions about screening are in-
formed by evidence rather than political considerations. Con-
gress’s paternalistic response toUSPSTFmammography screening
recommendations vividly illuminates the social costs of politically
mandated care. Rather than benefiting women, political interfer-
encewith science candiscourage shareddecisionmaking, increase
harms from screening, and foster public doubt about the value and
integrity of science.
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